Evidence map›Paper›PMID 38873424›Full record

ArticleFrontiers in pharmacology2024

Targeting

Luis Daniel Goyzueta-Mamani, Haruna Luz Barazorda-Ccahuana, Mayron Antonio Candia-Puma, Alexsandro Sobreira Galdino, Ricardo Andrez Machado-de-Avila, Rodolfo Cordeiro Giunchetti, José L Medina-Franco, Mónica Florin-Christensen, Eduardo Antonio Ferraz Coelho, Miguel Angel Chávez-Fumagalli

Abstract read
In one paragraph

Article in Frontiers in pharmacology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Luis Daniel Goyzueta-MamaniComputational Biology and Chemistry Research Group, Vicerrectorado de Investigación, Universidad Católica de Santa María, Arequipa, Peru.
Haruna Luz Barazorda-CcahuanaComputational Biology and Chemistry Research Group, Vicerrectorado de Investigación, Universidad Católica de Santa María, Arequipa, Peru.
Mayron Antonio Candia-PumaComputational Biology and Chemistry Research Group, Vicerrectorado de Investigación, Universidad Católica de Santa María, Arequipa, Peru.
Alexsandro Sobreira GaldinoLaboratório de Biotecnologia de Microrganismos, Universidade Federal São João Del-Rei, Divinópolis, Brazil.
Ricardo Andrez Machado-de-AvilaPrograma de Pós-Graduação em Ciências da Saúde, Universidade do Extremo Sul Catarinense, Criciúma, Brazil.
Rodolfo Cordeiro GiunchettiLaboratório de Biologia das Interações Celulares, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil.
José L Medina-FrancoDIFACQUIM Research Group, Department of Pharmacy, School of Chemistry, Universidad Nacional Autónoma de México, Mexico City, Mexico.
Mónica Florin-ChristensenInstituto de Patobiología Veterinaria, CICVyA, Instituto Nacional de Tecnología Agropecuaria (INTA), Buenos Aires, Argentina.
Eduardo Antonio Ferraz CoelhoPrograma de Pós-Graduação em Ciências da Saúde: Infectologia e Medicina Tropical, Faculdade de Medicina, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil.
Miguel Angel Chávez-FumagalliComputational Biology and Chemistry Research Group, Vicerrectorado de Investigación, Universidad Católica de Santa María, Arequipa, Peru.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Visceral Leishmaniasis (VL) is a serious public health issue, documented in more than ninety countries, where an estimated 500,000 new cases emerge each year. Regardless of novel methodologies, advancements, and experimental interventions, therapeutic limitations, and drug resistance are still challenging. For this reason, based on previous research, we screened natural products (NP) from Nuclei of Bioassays, Ecophysiology, and Biosynthesis of Natural Products Database (NuBBE

Indexed as

drug discoverymolecular docking simulationmolecular dynamics simulationnatural productsOcotilloneSubsessilinevirtual screeningvisceral leishmaniasis

Identifiers

PMID38873424
PMCPMC11169604

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.